Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Esserman, Laura J., Berry, Donald A., Cheang, Maggie C. U., Yau, Christina, Perou, Charles M., Carey, Lisa, DeMichele, Angela, Gray, Joe W., Conway-Dorsey, Kathleen, Lenburg, Marc E., Buxton, Meredith B., Davis, Sarah E., van’t Veer, Laura J., Hudis, Clifford, Chin, Koei, Wolf, Denise, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debu, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Livasy, Chad, Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunni-Yi, Giri, Dilip, Au, Alfred, Hylton, Nola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332388/
https://www.ncbi.nlm.nih.gov/pubmed/22198468
http://dx.doi.org/10.1007/s10549-011-1895-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3332388/
https://www.ncbi.nlm.nih.gov/pubmed/22198468
http://dx.doi.org/10.1007/s10549-011-1895-2

Ejemplares similares